Capital International Investors Sells 1,850,708 Shares of Genmab A/S (NASDAQ:GMAB)

Capital International Investors decreased its holdings in Genmab A/S (NASDAQ:GMAB) by 41.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,570,909 shares of the company’s stock after selling 1,850,708 shares during the period. Capital International Investors’ holdings in Genmab A/S were worth $53,398,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. AIMZ Investment Advisors LLC purchased a new stake in Genmab A/S during the 4th quarter valued at approximately $3,525,000. HighTower Advisors LLC bought a new position in shares of Genmab A/S during the third quarter worth $273,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Genmab A/S by 229.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company’s stock valued at $1,033,000 after acquiring an additional 34,652 shares in the last quarter. Blue Trust Inc. increased its holdings in Genmab A/S by 33.4% in the 4th quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock valued at $120,000 after acquiring an additional 1,442 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Genmab A/S in the 4th quarter worth $2,463,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Wall Street Analyst Weigh In

GMAB has been the subject of a number of research analyst reports. Truist Financial cut their price objective on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. HC Wainwright reiterated a “buy” rating and set a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Finally, BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $39.17.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $20.04 on Monday. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $30.41. The firm has a 50-day simple moving average of $20.54 and a two-hundred day simple moving average of $21.14. The company has a market cap of $13.26 billion, a P/E ratio of 11.52, a PEG ratio of 2.65 and a beta of 1.07.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, equities research analysts expect that Genmab A/S will post 1.45 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.